Highest-materiality recent filing
Pediatrix Q2 2026: Adjusted EPS $0.63, revenue $488M, reaffirms FY EBITDA $280-300M
Net revenue $487.8M, up 4.0% YoY; net income $39.8M ($0.49 diluted EPS) vs $39.3M ($0.46) YoY.
Pediatrix Medical Group GC Mary Ann Moore to depart Oct 31; David Haddock appointed successor
Mary Ann Moore will transition to advisory role until October 31, 2026, then leave the company.
Pediatrix reaffirms FY 2026 Adjusted EBITDA guidance of $280M-$300M; payor mix stable
Payor mix for Q2 2026 remained stable and unchanged relative to recent historical trends and internal expectations.
Shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, increasing authorized shares by 8,000,000.
Pediatrix Q1 GAAP EPS $0.36, Adj. EPS $0.44; revenue $476M, beat expectations
Net revenue $476.2M, up 4% YoY from $458.4M; same-unit revenue grew 2.8%.
Pediatrix Q4 EPS $0.40; Adj. EPS $0.50; guides 2026 EBITDA $280-300M
Net revenue $494M, down slightly YoY; same-unit revenue up 4.0%.
Pediatrix Q3 EPS $0.84, revenue $493M; raises FY2025 Adj. EBITDA outlook to $270-290M
Net income $71.7M ($0.84/share) vs $19.4M ($0.23) year ago; adjusted EPS $0.67 vs $0.44.
Pediatrix Medical Group announces $250M share repurchase program with three-year term
Board authorized up to $250M in share repurchases of outstanding common stock over three years.
Pediatrix Q2 EPS $0.46, Adjusted $0.53; raises FY 2025 EBITDA guidance to $245-255M
Net revenue $469M; net income $39M vs. loss of $153M a year ago due to non-cash impairment.
Pediatrix appoints Dr. Kurt Newman as independent director effective July 1, 2025
Dr. Newman, former President & CEO of Children's National Hospital for 12 years, appointed to board.
Pediatrix shareholders elect all 8 director nominees, ratify PwC, approve say-on-pay
All 8 management director nominees elected with 70M+ votes each; broker non-votes of ~5.5M.
Pediatrix Q1 adjusted EPS $0.33; raises FY2025 EBITDA guidance to $220-240M
Net revenue $458M, down 7% YoY due to dispositions; same-unit revenue grew 6.2% on improved payor mix and volume.
Pediatrix extends Guidehouse services pact to June 30, 2025; adds SOW #2 from July 1
PMG Services and Guidehouse amended SOW #1 to extend term from April 19, 2025 through June 30, 2025.
Pediatrix Q4 net income $30M, Adjusted EPS $0.51, revenue up to $502M
GAAP EPS $0.36 (vs $1.50 loss Q4 2023); Adjusted EPS $0.51 (vs $0.32).
Mark S. Ordan appointed CEO of Pediatrix Medical Group effective Jan 12, 2025
Mark Ordan, 65, appointed CEO; he was CEO from 2020-2022 and most recently Executive Chair, succeeding Dr. Swift.
Pediatrix appoints Mark Ordan as CEO, expects 2024 adjusted EBITDA to exceed $215M guidance
Mark S. Ordan returns as CEO effective immediately, succeeding James D. Swift who will assist transition.
Dr. Curtis B. Pickert will transition from his roles as EVP, Chief Physician Executive and former COO effective January 31, 2025.
Pediatrix Q3 adjusted EPS $0.44, revenue $511M; reaffirms FY 2024 EBITDA guidance $205-215M
Net revenue $511M, up from $506.6M YoY; same-unit revenue grew 5.2% (reimbursement +3.4%, volume +1.8%).
Q2 net loss $153M ($1.84 loss per share) vs net income $28.3M ($0.34 EPS) in Q2 2023, driven by $192.9M impairment.
Pediatrix eliminates EVP role of Lee Wood; departure by July 5, 2024
Lee A. Wood's role as EVP of National and Market Operations eliminated effective July 5, 2024.
Company exiting office-based practices and primary/urgent care by end of 2024.
Pediatrix shareholders elect all 9 director nominees, ratify PwC, approve say-on-pay
All nine director nominees elected; votes for ranged from 72.6M to 74.1M, against 0.9M-2.3M.
Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M
Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.
Pediatrix enters 8-year revenue cycle management agreement with Guidehouse
PMG Services (Pediatrix subsidiary) signs Master Services Agreement with Guidehouse for enterprise revenue cycle management.
Pediatrix Q4 GAAP loss $1.50/share; adj EPS $0.32; 2024 EBITDA guidance $200-220M
GAAP diluted loss from continuing ops $1.50 vs income $0.29 a year ago; $168.3M non-cash impairment.
Pediatrix Q3 GAAP EPS $0.26, Adjusted EPS $0.32; FY guidance $200-210M
Q3 GAAP EPS $0.26 vs $0.35 YoY; Adjusted EPS $0.32 vs $0.40.
Pediatrix Q2 net revenue $500.6M (+3% YoY); GAAP EPS $0.34, adjusted $0.39; EBITDA $59M
GAAP EPS from continuing ops $0.34 vs $0.36; adjusted EPS $0.39 vs $0.47 in prior year.
All 8 director nominees elected; Michael Rucker received lowest support with 68.6M for, 7.3M against.
Pediatrix appoints Sylvia Young as independent director effective May 12
Board size increased to nine; Ms. Young appointed as independent director.
Pediatrix Q1 net rev $491M, GAAP EPS $0.17, adj EPS $0.23, reaffirms FY adj EBITDA $235-245M
Net revenue $491M, up 1.8% YoY; same-unit revenue up 2.0% driven by volume and collections.
CEO James D. Swift elected to Pediatrix board after director Roger J. Medel resigns
Roger J. Medel resigned from the Board effective March 7, 2023; no disagreement with the Company.
Pediatrix Q4 GAAP EPS $0.29, adjusted $0.47; revenue $514M; 2023 EBITDA guidance $235-245M
Net revenue $513.8M (+3.1% YoY); same-unit patient volume +4.1%; commercial payor mix improved 20 bps.
Pediatrix appoints Dr. James Swift as CEO; Mark Ordan becomes Executive Chair
James D. Swift, M.D., named CEO effective Jan 1, 2023; succeeds Mark S. Ordan.
Pediatrix Q3 adjusted EPS $0.40 misses; FY2022 EBITDA guidance lowered to $240-245M
Adjusted EPS from continuing operations $0.40 vs $0.46 YoY; GAAP EPS $0.35.
Pediatrix GC Dominic Andreano to step down; Mary Ann Moore appointed successor
Andreano to depart as EVP, General Counsel and Secretary effective Oct. 14, 2022.
Pediatrix Q2 adjusted EPS $0.47 vs $0.41 YoY; revenue up 2.7%; FY22 EBITDA outlook reaffirmed
GAAP EPS $0.36 flat YoY; adjusted EPS $0.47 vs $0.41 on revenue of $486M (+2.7%).
Mednax to rename to Pediatrix Medical Group effective July 1, 2022
Corporate name changes from Mednax, Inc. to Pediatrix Medical Group, Inc. after market close on July 1, 2022.
Mednax appoints James D. Swift as COO; shareholders reject say-on-pay
James D. Swift, MD promoted from EVP/Chief Development Officer to EVP/COO, effective May 12, 2022.
Mednax Q1 GAAP loss $0.25/sh includes $57M debt charge; adj EPS $0.33
Revenue $482M (+8% YoY); same-unit revenue +1.3%, volume +3.2%.
Dr. Hinson will transition from his role as President effective June 1, 2022.
Mednax Q4 EPS $0.47 ($0.52 adj); revenue $499M; FY22 EBITDA guidance at least $270M
GAAP EPS from continuing ops $0.47 versus $0.05 in Q4 2020; adjusted EPS $0.52 versus $0.25.
Mednax closes $1.1B financing, redeems $1B 6.25% notes due 2027
Issued $400M 5.375% senior notes due 2030, new $450M revolver and $250M term loan.
Mednax CFO Richards named PAO; Board adopts majority vote for directors; Moore promoted
CFO C. Marc Richards adds Principal Accounting Officer role effective immediately; John Pepia remains SVP/Chief Accounting Officer.
Mednax reports Q3 GAAP EPS $0.37 from continuing ops, revenue $493M, adjusted EPS $0.46
Net revenue $492.9M, up 7% YoY; same-unit revenue +5.9%, driven by 6.5% volume increase.
Mednax cuts revolving credit commitments from $1.2B to $600M; no outstanding balance
Revolving commitments reduced from $1.2 billion to $600 million effective August 23, 2021.
Mednax Q2: GAAP EPS $0.36, adj EPS $0.41, revenue $473M (+14% YoY), volume strong
Net revenue $473M vs $415.4M prior year; income from cont ops $30.5M ($0.36 diluted) vs $7.1M ($0.08).
appointed Mr. Mark S. Ordan to serve as the Company’s Chief Executive Officer and principal executive officer, succeeding Dr. James D. Swift.
succeeding Dr. James D. Swift.
Mr. Richards’ transition from his role as Executive Vice President, CFO and Treasurer is a termination without “Cause” pursuant to that certain Amended and Restated Employment Agreement
On August 6, 2024, the Company announced that its board of directors (the “Board”) has appointed Ms. Kasandra Rossi, who currently serves as the Company’s Senior Vice President, Financial Reporting and Assistant Treasurer, to succeed Mr. C. Marc Richards as Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer of the Company.
the Company announced that Curtis B. Pickert, M.D. has transitioned from his role as the Company’s Executive Vice President, Chief Operating Officer and will now serve as Pediatrix’s Executive Vice President, Chief Physician Executive, effective as of August 1, 2024.
The Company also announced that the Board has appointed Ms. Mary Ann E. Moore to serve as the Company’s Chief Administrative Officer, in addition to her existing roles as the Company’s Executive Vice President, General Counsel and Secretary, effective as of August 1, 2024.
On June 17, 2024, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), notified Mr. Lee. A Wood that the Company was eliminating the role of Executive Vice President, National and Market Operations, effective as of July 5, 2024 (the “Effective Date”), as part of the Company’s previously announced continued focus on operating efficiency.
increased the size of the Company’s Board to nine (9) members and appointed Ms. Sylvia Young to serve as a Director of the Company, each effective as of May 12, 2023.
elected James D. Swift, M.D., the Company’s Chief Executive Officer, to the Board to fill a vacancy created by the resignation of Roger J. Medel M.D.
who resigned from the Board effective March 7, 2023.
Mr. Mark S. Ordan, who has been appointed as the Executive Chair of the Board
appointed James D. Swift, M.D., as the Company’s Chief Executive Officer and principal executive officer to succeed Mr. Mark S. Ordan
Max materiality 0.85 · Median 0.65 · Most common event earnings